La chaîne d'options affiche les données clés des options sur actions de Kubota à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Kubota..

Kubota (OTC:KUBTY) Stock, Chaîne d'Options

Kubota

Kubota manufactures and sells small and midsize agricultural and construction equipment as well as water treatment equipment. Its key products in the farm and industrial machinery segment include compact/utility tractors, mini excavators, compact track loaders, engines, and rice farming equipment, such as combine harvesters as well as rice transplanters. The company has produced over 5.4 million units of tractors worldwide and over 30 million units of engines. Its water and environment segment provides mainly pipe system products like ductile iron pipes and valves, water/waste treatment plants, pumps, as well as operation and maintenance services, including public-private partnership projects. The company is based in Osaka, Japan, and was founded in 1890.

Kubota Corp

Cantor Fitzgerald analyst Rick Bienkowski reiterates Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Overweight and maintains $55 price target.

News

Price Target

Reiteration

Analyst Ratings

LEGN

Cantor Fitzgerald Reiterates Overweight on Legend Biotech, Maintains $55 Price Target

Mizuho analyst James Lee maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Outperform and lowers the price target from $50 to $48.

Mizuho Maintains Outperform on JD.com, Lowers Price Target to $48

Barclays analyst Michael Leithead maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Equal-Weight and raises the price target from $59 to $62.

Barclays Maintains Equal-Weight on Celanese, Raises Price Target to $62

Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) announced on Wednesday that its board of directors approved a new $6 billion <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45405418/amd-announces-new-6-billion-share-repurchase-authorization" rel="noreferrer noopener">share repurchase program</a>.
The new authorization is in addition to the remaining balance, as of March 29, of approximately $4 billion of its existing share repurchase program, increasing the total current repurchase authority to roughly $10 billion.
The stock is trading higher after the update.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45384346/amd-launches-epyc-4005-chips-for-small-business-and-cloud" target="_blank" rel="noreferrer noopener">AMD Launches EPYC 4005 Chips For Small Business And Cloud</a>
AMD stock is down close to 7% year-to-date. Uncertainty surrounding U.S. tariff policies took a toll on the entire sector.
The company is engaged in intensifying competition with Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) GPUs.
However, semiconductor stocks got a boost this week after Beijing and Washington <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45352452/why-are-nvidia-and-other-chip-stocks-trading-higher-on-monday" rel="noreferrer noopener">temporarily agreed to</a> lower tariffs on each other&#8217;s products. Bloomberg reported on Wednesday, citing unnamed sources familiar with the matter, that the US also looks to rescind the Biden administration&#8217;s artificial intelligence diffusion, which created three broad tiers of access for countries seeking AI chips and would have taken effect May 15. Instead, the US government is drafting its approach and could forge individual deals with countries.
President Trump also announced <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/05/45390422/trump-unveils-historic-and-transformative-600-billion-saudi-deal-predicts-markets-will-go-a-lot-higher" rel="noreferrer noopener">multi-billion dollar commercial</a> deals from Saudi Arabia with&nbsp;companies, including Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and AMD.
AMD held $7.31 billion in cash and equivalents as of March 29, 2025.
Last week, AMD reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45237261/amd-q1-earnings-revenue-eps-beat-driven-by-expanding-data-center-ai-momentum-chipmaker-expects-strong-growth-in-2025" rel="noreferrer noopener">first-quarter revenue</a> of $7.44 billion, up 36%, topping analyst estimates of $7.13 billion. The chipmaker reported first-quarter adjusted earnings of 96 cents per share, beating analyst estimates of 94 cents per share.
AMD expects second-quarter revenue of approximately $7.4 billion, plus or minus $300 million. Analysts are currently forecasting second-quarter revenue of $7.24 billion.
Price Action: AMD stock traded higher by 7.92% to $121.15 at Wednesday&#8217;s last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45379380/can-corning-broadcom-deal-transform-ais-data-center-future" target="_blank" rel="noreferrer noopener">Can Corning-Broadcom Deal Transform AI&#8217;s Data Center Future?</a></li>
</ul>
Image: Shutterstock

Buybacks

Tech

AMZN

NVDA

AMD Stock Pops On $6 Billion Buyback Plan, US Tariff Ease

Bitcoin Price gained 0.67% on Wednesday to reach $103,456.92, which took its weekly gain to 6.91% <a href="https://www.benzinga.com/money/how-to-buy-bitcoin-btc-best-bonuses-august-2024">and monthly to 22.59%</a>. The surge has resulted in Bitcoin gaining reputation as a long-term investment, as investors are now seeing it as more of ‘digital gold' than just a speculative asset.
The U.S. has been seeing rising yields on the 10-year Treasury note after a temporary withdrawal in tariffs between China and the U.S. This boosted the market sentiment and resulted in higher yields, which are currently 4.5%.&nbsp;
Typically, rising yields would signal trouble for non-yielding assets like Bitcoin as investors shift to safe interest-bearing assets. However, this situation is evolving.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade on</a> Coinbase. </li>
</ul>
David Lawant, head of research at FalconX, said that Bitcoin is being regarded as &#8220;emerging digital gold.&#8221; He added that despite the increased yields, Bitcoin&#8217;s unique properties are drawing lots of institutional attention. As the currency matures with the passage of time and there&#8217;s more clarity with respect to regulations, institutional investors are thinking about Bitcoin as a long-term repository of value, and not as a risky asset.
The institutional conviction was well on display recently, when a publicly listed firm, Next Technology, reported a $180 million purchase of Bitcoin, a 5,000-BTC addition to its treasury and bringing its holdings to 5,833 BTC.
Meanwhile, notable investors are also discussing the growth potential of Bitcoin. Arthur Hayes recently predicted that eventual U.S. monetary expansion would lead Bitcoin to reach $1 million. Anthony Scaramucci sees the network reaching 1 billion users and a $23 trillion market cap. Tim Draper, who holds 30,000 BTC, reasserted his prediction that Bitcoin would reach $250,000 per coin by year&#8217;s end. He even indicated Bitcoin could replace the U.S. dollar within a decade.
The trend does not end here. On Tuesday, a new investment company, Twenty One Capital, revealed that it has purchased 4,812 BTC valued at $458.7 million, according to BeInCrypto. The firm, founded by Jack Mallers, is supported by industry giants such as Tether, Bitfinex, Cantor Fitzgerald, and SoftBank.
The deal was financed via a PIPE deal and used proceeds of convertible notes. The company describes this as the start of a Bitcoin-native corporate strategy, which they have modeled after the aggressive treasury playbook, initially developed by Michael Saylor&#8217;s Strategy (then MicroStrategy).
As reported by BeInCrypto, Twenty One Capital now has $4.05 billion in BTC, which makes it the third-largest corporate holder of Bitcoin globally, after Strategy and Marathon Digital. Bitcoin advocate, Max Keiser, called this action &#8220;the next wave of Saylorization&#8221; and warned that companies would need to follow similar strategies or they would risk falling behind.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Bitcoin Considered 'Digital Gold' While It Reaches $103K

Rumors

IPOs

ETOR

Etoro Group IPO Price Indicating $62.50 On 500K Shares; IPO Priced At $52/Share On 11,923,018 Shares

Mizuho analyst Ann Hynes maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Neutral and lowers the price target from $37 to $32.

ACHC

Mizuho Maintains Neutral on Acadia Healthcare Co, Lowers Price Target to $32

A $30 million wipeout in just 60 days—no miscalculation, just tariffs. That's the reality a U.S. entrepreneur recently revealed following President <a href="https://www.benzinga.com/startups/24/09/40969537/trump-familys-crypto-venture-revealed-new-buying-rules-who-can-invest-and-what-it-means-for-early-ad">Donald Trump</a>'s imposition of a 145% tariff on Chinese goods.&nbsp;
On April 17, Mark Cuban shared a <a href="https://x.com/mcuban/status/1911097441580892491?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1911097441580892491%7Ctwgr%5Ed38d2889f79fbcd59e7beabb58b0d9f525b10b38%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fen.as.com%2Flatest_news%2Fmark-cubans-post-about-an-entrepreneurs-frustration-with-tariffs-what-this-is-going-to-do-to-our-economy-is-frightening-n%2F">post on X</a>. In it, he amplified concerns voiced by an unnamed entrepreneur about the growing damage many businesses say they're now grappling with under Trump's newly unveiled trade plans. The tariffs, which would impact imports from 185 countries, start at 10%, with China facing the steepest rate.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
<h2 class="wp-block-heading">Businesses Stall, Stock Warnings Grow Louder</h2>
In his post, Cuban quoted the entrepreneur, who said, "$30M in EBITDA wiped out for us in 2 months, a company I spent a decade building decimated in a matter of months. Unbelievable people still don't understand tariffs at this point, and the head in the sand approach to what this is going to do to our economy is frightening. We are in cash preservation mode and have paused all shipments from China at this point."
Trump's trade measures aim to protect American manufacturing by making foreign imports more expensive. But some industries are already responding by freezing operations, cutting costs, and pausing international shipments.
According to <a href="https://www.reuters.com/business/autos-transportation/trumps-tariffs-chinese-parts-cybercab-semi-disrupt-teslas-us-production-plans-2025-04-16/">Reuters</a> on April 15, Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp; halted imports of components from China critical to the assembly of its Cybercab and Semi models. Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) redirected a 737 MAX jetliner meant for a Chinese airliner back to the U.S., citing prohibitive cost implications triggered by the tariff hike, according to media reports.&nbsp;
Trending: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
Retailers are also feeling the strain. On April 19, Marc Bowker, owner of Alter Ego Comics in Lima, Ohio, told <a href="https://www.businessinsider.com/main-street-trump-trade-war-tariffs-small-businesses-impact-2025-4">Business Insider</a> his supplier costs rose as much as 34%. The increase has forced him to raise prices on imported goods and tighten profit margins to stay afloat. "If you see prices go up at your local small business, it&#8217;s not because we want to,&#8221; he said . "It&#8217;s because we&#8217;re forced to."
Across the board, many small business owners are putting plans on hold according to data from the <a href="https://www.uschamber.com/small-business/small-business-weekly-forecast">U.S. Chamber of Commerce</a>. 12% of small business owners believe it&#8217;s a good time to expand, reflecting a five-point decline from January. Moreover, 19% are planning capital purchases in the next three months, down one point from January.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a>
Cuban encouraged consumers to stock up on essential household goods like soap, toothpaste, and medications, warning that tariffs would eventually drive up shelf prices nationwide.
Meanwhile, industry-wide concern is growing. A survey conducted by <a href="https://www.fictiv.com/ebooks/2025-state-of-manufacturing-report">Fictiv</a> revealed that 77% of manufacturing and supply chain leaders expressed concerns about their ability to manage resources effectively amid trade wars and <a href="https://www.benzinga.com/personal-finance/24/10/41313947/expert-finds-trumps-tax-proposal-drains-money-from-95-of-households-and-funnels-it-to-the-top-5-">tariffs</a>.
In addition, the <a href="https://www.uschina.org/news-releases/new-report-us-china-trade-war-2-0-poised-to-devastate-american-exporters/">U.S.-China Business Council</a> has estimated that some 862,467 American jobs—particularly in agriculture and trade-heavy sectors—could be at risk.
Read Next:
<ul class="wp-block-list">
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

TSLA

'Unbelievable People Still Don't Understand Tariffs' – Mark Cuban Highlights Entrepreneur's $30 Million Loss Under Trump's 145% Tariff

Cantor Fitzgerald analyst Kristen Kluska reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight and maintains $30 price target.

CAPR

Cantor Fitzgerald Reiterates Overweight on Capricor Therapeutics, Maintains $30 Price Target

Barclays analyst Michael Leithead maintains Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) with a Equal-Weight and lowers the price target from $61 to $57.

BALL

Barclays Maintains Equal-Weight on Ball, Lowers Price Target to $57

Mizuho analyst Ann Hynes maintains Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) with a Neutral and lowers the price target from $10 to $8.

FTRE

Mizuho Maintains Neutral on Fortrea Holdings, Lowers Price Target to $8

Trading Ideas

Etoro Group IPO Price Indicating $61.50 On 621K Shares; IPO Priced At $52/Share On 11,923,018 Shares

<a href="https://www.bloomberg.com/news/articles/2025-05-14/uber-targets-commuters-with-cheaper-pooled-rides-price-lock-pass?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-14/uber-targets-commuters-with-cheaper-pooled-rides-price-lock-pass?embedded-checkout=true</a>

General

UBER

'Uber Targets Commuters With Cheaper Pooled Rides, Price-Lock Pass'- Bloomberg

Barclays analyst Peter Lawson maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Underweight and lowers the price target from $1 to $0.46.

ADAP

Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $0.46

Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Neutral and lowers the price target from $30 to $20.

APLS

Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $20

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 10 years by 5.49% on an annualized basis producing an average annual return of 16.17%. Currently, Chemed has a market capitalization of $8.36 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 10 years ago, it would be worth $4,535.11 today based on a price of $571.49 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747233913_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chemed Stock In The Last 10 Years

Cantor Fitzgerald analyst Timur Ivannikov maintains Pharvaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>) with a Overweight and lowers the price target from $28 to $25.

PHVS

Cantor Fitzgerald Maintains Overweight on Pharvaris, Lowers Price Target to $25

Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported adjusted earnings of 62 cents per share on Tuesday for the first quarter of 2025, compared to 17 cents a year ago, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 36 cents</a>.
The cancer-focused company reported quarterly sales of $555.45 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45390263/exelixis-announces-first-quarter-2025-financial-results-and-provides-corporate-update" rel="noreferrer noopener">consensus of $498.18 million</a>.
Total revenues included net product revenues of&nbsp;$513.3 million, compared to&nbsp;$378.5 million&nbsp;for the comparable period in 2024.
<ul class="wp-block-list">
<li>The increase in net product revenues was primarily due to an increase in sales volume and an increase in average net selling price.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44499265/fda-approves-exelixis-lead-cancer-drug-cabometyx-for-expanded-use-in-neuroendocrine-tumors" rel="noreferrer noopener">FDA Approves Exelixis&#8217; Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors</a>
&#8220;Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in Cabometyx demand, new patient starts, and revenues,&#8221; said Michael M. Morrissey, president and CEO of Exelixis.
&#8220;The&nbsp;Exelixis&nbsp;commercial team rapidly mobilized for the launch of CABOMETYX in advanced neuroendocrine tumors (NET) within hours of receiving&nbsp;U.S.&nbsp;regulatory approval in late March. We are very pleased with the initial reception and plan to provide further updates to our 2025 financial guidance as we build momentum on the NET launch and gain further clarity on additional revenue opportunities for 2025,&#8221; Morrissey added.
Guidance: &#8220;Based on the strong first quarter dynamics of CABOMETYX, we&#8217;re increasing our 2025 full year financial guidance for net product revenues and total revenues by&nbsp;$100 million,&#8221; Morrissey said.
The company raised fiscal 2025 sales guidance from $2.15 billion—$2.25 billion to $2.25 billion—$2.35 billion, versus the consensus of $2.25 billion.
On Tuesday, Invenra Inc. announced that its collaboration partner, Exelixis, has initiated the dose-escalation stage of the first-in-human Phase 1 study of XB628 in participants with recurrent advanced or <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">metastatic solid tumors</a>.
XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45394458/invenra-highlights-exelixis-initiation-of-phase-1-clinical-study-evaluating-xb628-a-first-in-class" rel="noreferrer noopener">death-ligand 1 (PD-L1)</a>.
The molecule was discovered in part through a collaboration between Exelixis and Invenra.
&#8220;Regarding flagship product Cabometyx, we are encouraged by its continued strength in RCC and expect the recent approval in late-line NETs to potentially drive the next leg of growth,&#8221; William Blair analyst Andy T. Hsieh wrote on Wednesday.
&#8220;The NETs market is expected to grow at a 9% compound annual rate to $4.6 billion by 2030. Based on our prior analysis, the total addressable market for Cabometyx in this indication stands at $900 million, thus representing a material expansion opportunity, in our view.&#8221; 
Price Action: At the last check on Wednesday, EXEL stock was up 4.11% at $38.47 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45405716/firstcash-enters-uk-market-with-394-million-acquisition-of-ht-group" target="_blank" rel="noreferrer noopener">FirstCash Enters UK Market With $394 Million Acquisition Of H&amp;T Group</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Earnings

Guidance

Health Care

Movers

EXEL

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is doing well lately, gaining 3.56% in the last 24 hours. Currently trading for $0.2329, the meme coin provided returns of 34.16% last week, and is up <a href="https://www.benzinga.com/money/how-to-buy-dogecoin-doge">41.76% in the last month.</a>&nbsp;
The recent uptick in Dogecoin price is due to a recent SEC announcement for its ETF.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
On Tuesday, the Securities and Exchange Commission (SEC) put its 21Shares Dogecoin ETF proposal on hold. While a delay is typically seen as negative, the context behind this decision might be positive.
The Securities and Exchange Commission has requested public feedback on the Dogecoin ETF, 21Shares. It signals that the agency is seriously contemplating the ETF. Since the current Donald Trump administration took office, the SEC has been significantly more lenient on crypto. It has dismissed many crypto lawsuits and shown openness to new ETF structures, such as in-kind redemptions.
The decision is important for Dogecoin because ETF approval, even pending, tends to legitimize a token in the eyes of institutional investors. If the 21Shares Dogecoin ETF is approved within the coming months, it would be the first time that a meme coin is given such formal financial treatment. This may lead to even more capital flows into the asset.
On broader market performance, Dogecoin was one of the week&#8217;s top performers. Additionally, crypto markets reacted positively to April&#8217;s consumer price index, which was surprisingly lower than expected. A lower price index may lead to a rate cut by the Federal Reserve later this year. If this happens as the markets hope, it will be beneficial for risk-on assets such as cryptocurrency.
Adding to the optimism, Coindesk reported that the Fear &amp; Greed Index, a popular sentiment indicator, has remained in &#8220;greed&#8221; territory for four consecutive days. It implies a strong demand from investors. While some traders have warned against short-term profit-taking due to the surging dollar and ongoing trade tensions, Dogecoin has continued to benefit from the momentum wave.
Dogecoin is demonstrating that it possesses long-term staying power within the world of crypto. Its steady trading volumes, community backing, and recent price action are generating strong interest.&nbsp;
The coin has now achieved a market cap of over $35.09 billion. If Dogecoin ultimately gets the ETF approval and the market conditions remain favorable, it won't be wrong to say that Dogecoin could rise from the meme coin stigma, and find a stable place in institutional portfolios.
For now, Dogecoin is doing really well be it on speculative terms, sentiment, or signs of institutional adoption. Whether or not the rally will continue will depend on regulatory decisions and overall market forces, but Dogecoin is certainly back in the game.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

$DOGE

Dogecoin Surges Over 34% in a Week amid ETF Delay by the SEC

Barclays analyst Andrew Mok maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Equal-Weight and lowers the price target from $35 to $28.

Comments

Kubota

Kubota (KUBTY) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL